Michael L. Grossbard, MD, discusses the phase III DYNAMO study examining the use of duvelisib in the treatment of patients with indolent non-Hodgkin lymphoma.
Michael L. Grossbard, MD, professor in the Department of Medicine, chief of the Hematology and Medical Oncology Inpatient Service at Tisch Hospital, and section chief of Hematology at NYU Langone Health’s Perlmutter Cancer Center, discusses the phase III DYNAMO study examining the use of duvelisib (Copiktra) in the treatment of patients with indolent non-Hodgkin lymphoma.
The phase II DYNAMO study evaluated the safety and efficacy the next-generation PI3K inhibitor duvelisib in patients with indolent non-Hodgkin lymphomas that were refractory to rituximab (Rituxan) and either chemotherapy or radioimmunotherapy, says Grossbard.
Duvelisib has some advantages in that it is a dual PI3K inhibitor, meaning that it works on 2 different isoforms of the enzyme. As such, it has the chance to be more effective, targeted, and cytotoxic compared with earlier-generation PI3K inhibitors, explains Grossbard.
The DYNAMO study showed very high response rates with the PI3K inhibitor in patients with previously treated follicular lymphomas. Specifically, the objective response rate with the agent was 42.2% in these patients and the median duration of response was approximately 1 year, says Grossbard. Duvelisib serves as an oral option for patients who have failed chemotherapy or rituximab-based therapy that can potentially buy them additional time, concludes Grossbard.